临床试验 以下为当前的临床试验。7 研究 骨髓移植项目。 (仅限仍在招募的研究). 按院区、状态和其他条件筛选该研究列表。 A Study to Assess Feasibility and Benefit of a Patient-reported Outcomes Quality of Life Tool for Hematology and Medical Oncology Scottsdale/Phoenix, Ariz. The purpose of this study is to determine the feasibility and benefit of a patient-reported outcomes quality of life tool for hematology and medical oncology. A Study to Evaluate Cancer Distress, Psychological Trauma, and Resiliency in Hospitalized Hematopoietic Stem Cell Transplant Patients Jacksonville, Fla. The purpose of this study is to better understand the distress experience of hospitalized patients undergoing hematopoietic stem cell transplant (HSCT), and to examine the relationship between cancer distress, psychological trauma, and resiliency over time. A Study to Evaluate Immune and Hematopoietic Cell Assessment in Clonal B Cell Conditions Rochester, Minn. The purpose of this study is to evaluate the immune and hematopoietic compartments in patients with monoclonal B cell lymphocytosis (MBL) and chronic lymphocytic leukemia (CLL) in comparison to age-matched healthy control (HC) donors. A Study to Evaluate the Role of Gut Microbiome in Cancer Therapy Jacksonville, Fla., Rochester, Minn., Scottsdale/Phoenix, Ariz. The purpose of this study is to correlate gut microbiome with specific cancer diagnoses and the clinical response (effectiveness), and adverse effects of cancer therapy (single or multiple) and stem cell transplant. Hematopoietic Stem Cell Transplant Survivors Study (HTSS Study) Rochester, Minn. The investigators hope to find the proof of principle concept from this pilot study so that the investigators can design a clinical trial based on the results of the explanatory hypothesis. A Study to Assess Older Adults Applying Pre-transplant Comorbidity, Geriatric Assessment and Biomarkers to Predict Non-Relapse Mortality After Allogeneic Transplant (CHARM) Rochester, Minn., Scottsdale/Phoenix, Ariz. The purpose of this study is to determine the set of assessments and biomarkers that could together constitute a robust and valid composite health risk model for accurate personalized estimation of one year NRM. Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission Rochester, Minn., Jacksonville, Fla. This randomized phase III trial studies rituximab after stem cell transplant and to see how well it works compared with rituximab alone in treating patients with in minimal residual disease-negative mantle cell lymphoma in first complete remission. Monoclonal antibodies, such as rituximab, may interfere with the ability of cancer cells to grow and spread. Giving chemotherapy before a stem cell transplant helps kill any cancer cells that are in the body and helps make room in the patient's bone marrow for new blood-forming cells (stem cells) to grow. After treatment, stem cells are collected from the patient's blood and stored. More chemotherapy is then given to prepare the bone marrow for the stem cell transplant. The stem cells are then returned to the patient to replace the blood-forming cells that were destroyed by the chemotherapy. Giving rituximab with or without stem cell transplant may work better in treating patients with mantle cell lymphoma. 申请预约 位置、旅行和住宿研究 May 09, 2023 妙佑医疗国际明尼苏达州罗切斯特院区和亚利桑那州凤凰城/斯科茨代尔院区均被《美国新闻与世界报道》评为 2022-2023 全美顶尖癌症医院。 了解更多关于这一最高荣誉的信息 骨髓移植项目。科室首页部分申请预约概述测试与程序主治医生专业团队专长与排名位置、旅行和住宿临床试验研究患者故事费用与保险Mayo Clinic 新闻资格结局转诊联系我们 研究:以患者为中心 部分申请预约概述测试与程序主治医生专业团队专长与排名位置、旅行和住宿临床试验研究患者故事费用与保险Mayo Clinic 新闻资格结局转诊 ORG-20193492 医学科室与中心 骨髓移植项目。